| answer text |
<p>Public Health England will monitor vaccine effectiveness in different targeted
groups using a range of existing surveillance systems, new enhanced surveillance and
by building upon established research studies in specific populations.</p><p>UK Research
and Innovation has provided initial funding of £1.8 million towards the OCTAVE study
in supporting research on vaccine responses in groups of immune-supressed individuals,
including those with inflammatory disorders, high risk cancer patient groups, and
patients with severe kidney and liver disease. Cancer patient groups include chronic
lymphocytic leukaemia, myeloma, acute leukaemia and bone marrow transplants.</p>
|
 |
